Adzersen K, Friedrich S, Becker N (2016) Are epidemiological data on lymphoma incidence comparable? Results from an application of the coding recommendations of WHO, InterLymph, ENCR and SEER to a cancer registry dataset. J Cancer Res Clin Oncol 142:167–175
Ardeshna KM, Smith P, Norton A et al (2003) British national lymphoma investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362(9383):516–522
Article CAS PubMed Google Scholar
Armitage J (2007) How I treat patients with diffuse large B-cell lymphoma. Blood 110(1):29–36
Article CAS PubMed Google Scholar
Blümel M, Spranger A, Achstetter K et al (2020) Germany: health system review. Health Syst Transit 22(6):1–273
Bögemann M, Zagorska A, Akumo D et al (2020) Using data from a sickness fund claims database to assess the treatment patterns and healthcare resource utilization among patients with metastatic renal cell carcinoma in Germany. Urol Int 104(11–12):982–993
Borchmann P, Heger J-M, Mahlich J et al (2023) Healthcare resource utilization and associated costs of German patients with diffuse large B-cell lymphoma—a retrospective health claims data analysis. Oncol Ther 11:65–81. https://doi.org/10.1007/s40487-022-00211-6
Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808
Article CAS PubMed PubMed Central Google Scholar
Czwikla J, Domhoff D, Giersiepen K (2016) ICD coding quality for outpatient cancer diagnoses in SHI claims data. Z Evid Fortbild Qual Gesundh Wesen 118:48–55
Daneels W, Rosskamp M, Macq G et al (2022) Real-world estimation of first- and second-line treatments for diffuse large B-cell lymphoma using health insurance data: a Belgian population-based study. Front Oncol 12:824704
Article PubMed PubMed Central Google Scholar
Durmaz M, Visser O, Posthuma E et al (2022) Time trends in primary therapy and relative survival of diffuse large B cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018. Blood Cancer J 12(3):38
Article PubMed PubMed Central Google Scholar
Ekberg D, Crowther M et al (2022) Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission. Br J Cancer 127:1642–1649
Article PubMed PubMed Central Google Scholar
Epperla N, Vaughn J, Othus M et al (2020) Recent survival trends in diffuse large B-cell lymphoma––have we made any progress beyond rituximab? Cancer Med 9:5519–5525
Article CAS PubMed PubMed Central Google Scholar
Fu K, Weisenburger D, Choi W et al (2008) Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B cell-like and non-germinal center B cell-like subtypes of diffuse large B cell lymphoma. J Clin Oncol 26(28):4587–4594
Article CAS PubMed Google Scholar
GBA [Gemeinsamer Bundesauschuss] (2020) Nutzenbewertungsverfahren zum Wirkstoff Polatuzumab Vedotin. Available: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/518/#dossier. Accessed 30 Aug 2022
Gisselbrecht C, Van Den Neste E (2018) How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol 182:633–643
Article PubMed PubMed Central Google Scholar
Jabbour E, Thomas D, Cortes J, Kantarjian HM, O’Brien S (2010) Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116:2290–2300
Kanas G, Ge W, Quek R et al (2022) Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020–2025. Leuk Lymphoma 63(1):54–63
Article CAS PubMed Google Scholar
Larouche JF, Berger F et al (2010) Lymphoma recurrence 5 years or later following diffuse large B-Cell lymphoma: clinical characteristics and outcome. J Clin Oncol 28(12):2094–2100
Mahlich J, Alba A, El Hadad L et al (2019) Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis. Adv Ther 36(7):1684–1699
Article CAS PubMed Google Scholar
Mahlich J, Olbrich K, Wilk A et al (2021) Time to treatment discontinuation in German patients with Schizophrenia: Long acting injectables versus oral antipsychotics. Clin Drug Investig 41(1):99–113
Article CAS PubMed Google Scholar
Moertl B, Dreyling M, Schmidt C et al (2022) Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): a health economic perspective. Clin Lymphoma Myeloma Leuk 22(7):474–482
Morrison VA, Bell JA, Hamilton L et al (2018) Economic burden of patients with diffuse large B cell and follicular lymphoma treated in the USA. Future Oncol 14:2627–2642
Article CAS PubMed Google Scholar
NIH [National Institutes of Health] (2022) Surveillance, Epidemiology, and End Results (SEER). Cancer Stat Facts: NHL - Diffuse Large B-Cell Lymphoma (DLBCL). Available online: https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed 20 Oct 2022
Pavlovsky M, Cubero D, Agreda-Vasquez G et al (2022) Clinical outcomes of patients with B cell non-Hodgkin lymphoma in real-world settings: findings from the hemato-oncology Latin America observational registry study. JCO Global Oncology 8:e2100265
Article PubMed PubMed Central Google Scholar
Pulte D, Jansen L, Gondos A et al (2013) Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century. Leuk Lymphoma 54(5):979–985
Purdum A, Tieu R, Reddy S, Broder M (2019) Direct costs associated with relapsed diffuse large B cell lymphoma therapies. Oncologist 24(9):1229–1236
Article CAS PubMed PubMed Central Google Scholar
Scheid C, Kudernatsch R, Eckart M et al (2022) Treatment pathways and health outcomes of German patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation: a retrospective health claims data analysis. Drugs Real World Outcomes 9:577–588
Article PubMed PubMed Central Google Scholar
Scheid C, Kudernatsch R, Eckart M et al (2023) Incidence of graft-versus-host-disease in Germany: evidence from health care claims data. J Public Health. https://doi.org/10.1007/s10389-022-01736-w
Shaw J, Harvey C, Richards C et al (2019) Temporal trends in treatment and survival of older adult diffuse large B cell lymphoma patients in the SEER-Medicare linked database. Leuk Lymphoma 60(13):3235–3243
Article CAS PubMed Google Scholar
Tsutsué S, Tobinai K, Yi J et al (2020) Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B cell lymphoma. PLoS ONE 15(8):e0237509
Article PubMed PubMed Central Google Scholar
Wolff-Menzler C, Mahlich J, Olbrich K et al (2021) Hospitalisierungen und Behandlungskosten von Schizophreniepatienten nach Umstellung auf Depot-Antispsychotika. Gesundheitsökonomie und Qualitätsmanagement 26(6):302–309
Yamamoto M, Suzuki I, Saitou K et al (2020) Impact of comorbidity and relative dose intensity on outcomes in diffuse large B cell lymphoma patients treated with R-CHOP. J Cancer Res Clin Oncol 146:2995–3002
Article CAS PubMed Google Scholar
Yang X, Laliberté F, Germain G et al (2021) Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B cell lymphoma in the US. Oncologist 26(5):e817–e826
Article CAS PubMed PubMed Central Google Scholar
Zelenetz A, Gordon L, Wierda W et al (2016) Diffuse large B cell lymphoma version 1. J Natl Compr Canc 14(2):196–231
留言 (0)